Watch More Highlights

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses mantle cell lymphoma and what advanced practitioners should know about improving outcomes in relapsed and refractory disease with BTK inhibitors such as treatment with pirobrutinib; other new agents such as parsaclisib, a PI3K delta inhibitor, and the bispecific agent epcoritamab; and CAR T-cell therapy. She also relays some clinical pearls on toxicity management (including financial toxicity) and supportive care.

 

Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.